pharmaphorum |
AstraZeneca Shares Rise as Investors Shrug Off Mixed Diabetes Results
TheStreet.com Reduced cardiovascular risk means that Bydureon Exscel has met its primary safety objective under Food & Drug Administration rules, which dictate that type II diabetes treatments must not increase cardiovascular risk. However, the drug did not meet its ... AstraZeneca: Bydureon EXSCEL Trial Meets Primary Safety Goal In Type-2 Diabetes AZ's Bydureon disappoints in diabetes outcomes trial AstraZeneca diabetes trial meets safety objective |
Social Plugin